|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-12-24
|
|
pubmed:abstractText |
Protein kinase inhibitors (PKI) have become prominent agents in cancer therapeutics. However, the specificity for target kinase inhibition can be poor and unwanted effects can emerge in combination regimens. The PKI emodin, for instance, can produce mixed results when combined with cisplatin, and we have sought a biochemical pharmacologic explanation for the negative cytotoxic effects.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
427-36
|
|
pubmed:dateRevised |
2011-1-14
|
|
pubmed:meshHeading |
pubmed-meshheading:19529937-Antineoplastic Agents,
pubmed-meshheading:19529937-Cation Transport Proteins,
pubmed-meshheading:19529937-Cell Line, Tumor,
pubmed-meshheading:19529937-Cell Proliferation,
pubmed-meshheading:19529937-Cell Survival,
pubmed-meshheading:19529937-Cisplatin,
pubmed-meshheading:19529937-DNA Adducts,
pubmed-meshheading:19529937-Dichlororibofuranosylbenzimidazole,
pubmed-meshheading:19529937-Dose-Response Relationship, Drug,
pubmed-meshheading:19529937-Drug Synergism,
pubmed-meshheading:19529937-Emodin,
pubmed-meshheading:19529937-Female,
pubmed-meshheading:19529937-Humans,
pubmed-meshheading:19529937-Inhibitory Concentration 50,
pubmed-meshheading:19529937-Intracellular Space,
pubmed-meshheading:19529937-Nucleic Acid Synthesis Inhibitors,
pubmed-meshheading:19529937-Ovarian Neoplasms,
pubmed-meshheading:19529937-Protein Kinase Inhibitors,
pubmed-meshheading:19529937-RNA Interference,
pubmed-meshheading:19529937-Spectrophotometry, Atomic,
pubmed-meshheading:19529937-Time Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.
|
|
pubmed:affiliation |
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 353, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
